Seattle-based biotech Alpine Immune Sciences (Nasdaq: ALPN) is raising $100 million through an underwritten public offering.
With the new funding, announced Tuesday, Alpine co-founder and CEO Mitchell Gold said the biotech now has more than three years of runway. He added that the company, which now has about 130 people, has grown 65% over the past nine months, but he didn’t provide a target headcount growth for the near future.
